Factors Affecting the Recurrence of Giant Cell Tumor of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center

Abstract

Background/Aims: This aim of the present study was to identify specific markers determining the recurrence of the giant cell tumor of bone (GCTB). Methods: This study involved the clinicopathological analysis of 80 cases. All of the clinical features, pathological fracture, Campanacci grade, histological features and surgical methods were reviewed. Immunohistochemistry was used to detect the expression of Ki-67, CD147, mutant p53 and p63 in GCTB. Comparisons between different groups were performed using the Chi-square test. The risk factors affecting recurrence were analyzed using a binary logistic model. Kaplan-Meier analysis was employed for the survival analysis between the groups. Cell proliferation assays, migration and invasion assays were used to detect the function of CD147 on GCTB in vitro. Results: The univariate analysis showed that Ki-67 and CD147 expression, pathological fracture, Campanacci grade and surgical method were associated with recurrence. The multivariate analysis revealed that CD147 expression, Campanacci grade and surgical method were the factors affecting GCTB recurrence. In addition, the Kaplan-Meier analysis revealed that these factors affected tumor-free survival time. In vitro study revealed that the CD147 knockdown by small interfering RNA (siRNA) technique dramatically reduced the proliferation, migration and invasion of GCTB. Conclusion: Our results suggest that CD147 may serve as an adequate marker for GCTB recurrence. Campanacci grade is a risk factor for GCTB recurrence, which is also affected by the surgical method used.

Is Overexpression of Ki-67 a Prognostic Biomarker of Upper Tract Urinary Carcinoma? A Retrospective Cohort Study and Meta-Analysis

“…DFS was considered the interval between the date of UTUC surgery and the time of appearance of the first locoregional recurrence or distant metastasis. CSS was defined as the interval between the date of UTUC surgery and the time of UTUC-related death [27]. The potential prognostic factors were established by univariate analysis, and only the significant factors were entered into multivariate Cox proportional hazard regression models.…”

Survival and prognostic factors analyses in malignant giant cell tumor of bone

“…Based on the Campanacci classification, which has been widely accepted in evaluating giant cell tumor, grade III represented the aggressive type. A series of studies reported Campanacci grade III as the risk factor for tumor recurrence [19,20] and lung metastasis [21,22]. The recurrence was also reported to be a risk factor for resulting in metastasis [21,22].…”

Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone

“…The term "malignancy in GCTB" is used by the World Health Organization to describe such tumors, which show malignant potential and can completely transform into malignant tumors [25,26]. Currently, preoperative prediction and postoperative monitoring of GCTB patient prognosis are limited and mostly rely on patients' general information, radiological features, treatment history, and tumor pathological reports [1,4,5]. Therefore, identification of sensitive and specific factors that can predict tumor progression and prognosis, particularly those found in the serum, are urgently required.…”

“…GCTB predominantly occurs in the metaphysis, thoracic vertebra, and sacrum of individuals in their third and fourth decades of life and shows a female predilection [1,[3][4][5]. This kind of tumor is osteolytic and comprises three major cell populations: osteoclast-like multinuclear giant cells, mononuclear precursors of osteoclasts, and spindle-shaped stromal cells (GCTSCs) [6][7][8].…”